217
Participants
Start Date
July 25, 2025
Primary Completion Date
August 31, 2030
Study Completion Date
October 31, 2030
Del-desiran (AOC 1001)
Del-desiran will be administered by intravenous (IV) infusion.
University of Rochester Medical Center, Rochester
Virginia Commonwealth University, Richmond
University of Florida, Gainesville
Ohio State University, Columbus
Kansas University Medical Center, Kansas City
Houston Methodist Neurological Institute, Houston
University of Colorado, Denver
University of California, Los Angeles (UCLA), Los Angeles
Stanford University, Stanford
Lead Sponsor
Avidity Biosciences, Inc.
INDUSTRY